Inactive Instrument

Highlights Checkmate Pharmaceuticals, Inc.

Equities

CMPI

US1628181083

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Regeneron Completes Checkmate Pharmaceuticals Deal, Triggers $5 Million Milestone Payment to Kuros Biosciences	02/06/22	MT
Kuros To Receive $5 Million Milestone Payment from Regeneron's Acquisition Of Checkmate	02/06/22	MT
Regeneron Pharmaceuticals, Inc. completed the acquisition of Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others.	26/05/22	CI
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology Annual Meeting	26/05/22	CI
CHECKMATE PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	12/05/22	AQ
Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	12/05/22	CI
Checkmate Pharmaceuticals Shares Take Flight on Regeneron Deal	19/04/22	DJ
Regeneron to Buy Checkmate Pharmaceuticals for About $250 Million	19/04/22	DJ
Regeneron Pharmaceuticals Agrees to Buy Checkmate Pharmaceuticals in $250 Million All-Cash Deal	19/04/22	MT
Regeneron Pharmaceuticals, Inc. entered into a definitive agreement to acquire Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others for approximately $250 million.	18/04/22	CI
Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research Annual Meeting	08/04/22	CI
Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	30/03/22	CI
CHECKMATE PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	30/03/22	AQ
Checkmate Pharmaceuticals, Inc. Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using Vidutolimod	20/12/21	CI
CHECKMATE PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	12/11/21	AQ
Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21	CI
Checkmate Pharmaceuticals Presents Final Clinical Data for Phase 1B Study Evaluating Vidutolimod At the Society for Immunotherapy of Cancer 36Th Annual Meeting	12/11/21	CI
Checkmate Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2021	12/08/21	CI
CHECKMATE PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	12/08/21	AQ
Kuros Biosciences : Enters Royalty Purchase Deal With US-Based Xoma	15/07/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Checkmate Pharmaceuticals, Inc.

Equities

CMPI

US1628181083

Highlights

Filters